Why the study?
There is an ongoing need to identify new platinum compounds with improved efficacy, lower effective doses, and reduced side effects compared to existing chemotherapy agents like cisplatin.
The synthesis of two new phosphaplatin compounds provides insight into the structure-activity relationships of this class of molecules, despite lower cytotoxicity than the leading candidate.
New platinum complexes merit preclinical evaluation; leaves open clinical superiority over cisplatin.
High Resolution Image Download MS PowerPoint Slide Platinum complexes have now been used in chemotherapy regimens for almost half a century to treat a variety of cancers. The most clinically significant of these compounds to date is cisplatin, cis -diamminedichloroplatinum(II), whose clinical application has significantly reduced the mortality rate of several cancers. Despite this development, there is still a push to find new compounds that have improved efficacy, that can be administered at lower doses, and that produce less severe side-effects compared to current options. One class of molecules that may fill that role is phosphaplatins, an underexplored class of platinum(II) complexes that contain a bidentate pyrophosphate ligand. These compounds are anionic at physiological pH and display reduced DNA-binding compared to cisplatin. This study expands on the list of known phosphaplatins by introducing two new compounds, dicyclobutylaminedihydrogenpyrophosphatoplatinum(II) and dicyclopentylaminedihydrogenpyrophosphatoplatinum(II). Here we report complete synthetic details, as well as cell viability data in response to these compounds using two cancer cell lines, a human lung adenocarcinoma and a triple-negative human breast cancer. While these compounds inhibit cell viability less than the leading phosphaplatin drug candidate, trans -(1 R,2 R )-diaminocyclohexanedihydrogenpyrophosphatoplatinum(II), this work represents an important step in elucidating structure–activity relationships for this class of molecules.
No takes yet. Share an insight, caveat, or question.
Wagner et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: